Next, we applied our approach to peripheral blood TCR beta repertoire samples from 2 cytotoxic T-lymphocyte-associated protein 4 (CTLA4) checkpoint blockade cancer immunotherapy studies [20, 21]. Here, CTLA4 is linked to cancer.